Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea

Expert Review of Clinical Pharmacology

Volumn 7, Issue 5, 2014, Pages 567-577

  Tong, Lana X ^a   Moore, Angela Yen ^b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Arlington Center for Dermatology   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

brimonidine; brimonidine tartrate; facial erythema; rosacea; rosacea treatment; sansrosa

Indexed keywords

ANTIBIOTIC AGENT; AZELAIC ACID; BRIMONIDINE; ISOTRETINOIN; METRONIDAZOLE; RETINOID; SULFACETAMIDE PLUS SULFUR; TETRACYCLINE DERIVATIVE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; QUINOXALINE DERIVATIVE;

ARTICLE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; FACE ERYTHEMA; FACIAL FLUSHING; FLUSHING; HUMAN; INCIDENCE; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PREVALENCE; QUALITY OF LIFE; ROSACEA; SYSTEMIC THERAPY; TOPICAL TREATMENT; ANIMAL; ERYTHEMA; PATHOLOGY; TREATMENT OUTCOME;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ANIMALS; ERYTHEMA; HUMANS; QUALITY OF LIFE; QUINOXALINES; ROSACEA; TREATMENT OUTCOME;

EID: 84906258428     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.945910     Document Type: Article

References (87)

1. Tan J, Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol 2013; 69(6 Suppl 1):S27-35
2. Powell FC. The histopathology of rosacea: 'where's the beef?'. Dermatology 2004; 209(3):173-4
3. Steinhoff M, Buddenkotte J, Aubert J, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011;15(1):2-11
4. Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol 2013;69(6 Suppl 1):S15-26
5. Wilkin JK. Rosacea. Pathophysiology and treatment. Arch Dermatol 1994;130(3): 359-62
6. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002;46(4):584-7
7. Kyriakis KP, Palamaras I, Terzoudi S, et al. Epidemiologic aspects of rosacea. J Am Acad Dermatol 2005;53(5):918-19
8. Spoendlin J, Voegel JJ, Jick SS, Meier CR. A study on the epidemiology of rosacea in the U.K. Br J Dermatol 2012;167(3): 598-605
9. Augustin M, Herberger K, Hintzen S, et al. Prevalence of skin lesions and need for treatment in a cohort of 90 880 workers. Br J Dermatol 2011;165(4):865-73
10. Shim TN, Abdullah A. The effect of pulsed dye laser on the dermatology life quality index in erythematotelangiectatic rosacea patients: an assessment. J Clin Aesthetic Dermatol 2013;6(4):30-2
11. Romanowicz M, Stephenson JJ, Del Rosso JQ, Lenhart G. Healthcare utilization and costs of patients with rosacea in an insured population. J Drugs Dermatol 2008;7(1):41-9
12. Chosidow O, Cribier B. Epidemiology of rosacea: updated data. Ann Dermatol Venereol 2011;138(Suppl 3):S179-83
13. Elewski BE, Draelos Z, Dreno B, et al. Rosacea -global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol 2011;25(2):188-200
14. Jarmuda S, O'Reilly N, Zaba R, et al. Potential role of Demodex mites and bacteria in the induction of rosacea. J Med Microbiol 2012;61(Pt 11):1504-10
15. Whitfeld M, Gunasingam N, Leow LJ, et al. Staphylococcus epidermidis: a possible role in the pustules of rosacea. J Am Acad Dermatol 2011;64(1):49-52
16. Abram K, Silm H, Maaroos HI, Oona M. Risk factors associated with rosacea. J Eur Acad Dermatol Venereol 2010;24(5):565-71
17. Gerber PA, Buhren BA, Steinhoff M, Homey B. Rosacea: the cytokine and chemokine network. J Investig Dermatol 2011;15(1):40-7
18. Del Rosso JQ. The use of moisturizers as an integral component of topical therapy for rosacea: clinical results based on the Assessment of Skin Characteristics Study. Cuti 2009;84(2):72-6
19. Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol 2004;51(4):499-512; quiz 513-494
20. Wilkin JK. Effect of subdepressor clonidine on flushing reactions in rosacea. Change in malar thermal circulation index during provoked flushing reactions. Arch Dermatol 1983;119(3):211-14
21. Craige H, Cohen JB. Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol. J Am Acad Dermatol 2005; 53(5):881-4
22. Hsu CC, Lee JY. Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective beta-adrenergic blocker. J Am Acad Dermatol 2012;67(3):491-3
23. Papageorgiou P, Clayton W, Norwood S, et al. Treatment of rosacea with intense pulsed light: significant improvement and long-lasting results. Br J Dermatol 2008; 159(3):628-32
24. Tan SR, Tope WD. Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of life. J Am Acad Dermatol 2004;51(4):592-9
25. Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis 2014; 93(3):134-8
26. Tanghetti E, Del Rosso JQ, Thiboutot D, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 4: a status report on physical modalities and devices. Cutis 2014;93(2):71-6
27. Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies. Cutis 2014; 93(1):18-28
28. Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis 2013;92(6): 277-84
29. Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis 2013;92(5): 234-40
30. Fallen RS, Gooderham M. Rosacea: update on management and emerging therapies. Skin Ther Lett 2012;17(10):1-4
31. Fowler J Jr, Jackson M, Moore A, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol 2013;12(6):650-6
32. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol 2007;56(5):791-802
33. Ueyama Y, Misaki M, Ishihara Y, Matsumura T. Effects of antibiotics on human polymorphonuclear leukocyte chemotaxis in vitro. Br J Oral Maxillofacial Surg 1994;32(2):96-9
34. Kanada KN, Nakatsuji T, Gallo RL. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Investig Dermatol 2012;132(5):1435-42
35. Golub LM, Ciancio S, Ramamamurthy NS, et al. Low-dose doxycycline therapy: effect on gingival and crevicular fluid collagenase activity in humans. J Periodontal Res 1990; 25(6):321-30
36. Wise RD. Submicrobial doxycycline and rosacea. Comprehensive therapy. Summer 2007;33(2):78-81
37. Webster GF. An open-label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads). Cutis 2010;86(5 Suppl):7-15
38. Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol 2008;7(6):573-6
39. McKeage K, Deeks ED. Doxycycline 40 mg capsules (30 mg immediate-release/10 mg delayed-release beads): anti-inflammatory dose in rosacea. Am J Clin Dermatol 2010; 11(3):217-22
40. Akhyani M, Ehsani AH, Ghiasi M, Jafari AK. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol 2008;47(3):284-8
41. Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet 1976;1(7971):1211-12
42. Saihan EM, Burton JL. A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. Br J Dermatol 1980; 102(4):443-5
43. Coxon A, Pallis CA. Metronidazole neuropathy. J Neurol Neurosurg Psychiatry 1976;39(4):403-5
44. Wienbren M, Perinpanayagam RM, Camba L, Lee CA. Convulsions and encephalopathy in a patient with leukemia after treatment with metronidazole. J Clin Pathol 1985;38(9):1076
45. Plewig G, Nikolowski J, Wolff HH. Action of isotretinoin in acne rosacea and gram-negative folliculitis. J Am Acad Dermatol 1982;6(4 Pt 2 Suppl):766-85
46. Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol 1998;134(7):884-5
47. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004;51(3):327-41; quiz 342-324
48. Bonamigo RR, Bakos L, Edelweiss M, Cartell A. Could matrix metalloproteinase-9 be a link between Demodex folliculorum and rosacea? J Eur Acad Dermatol Venereol 2005;19(5):646-7
49. Gerber PA, Kukova G, Buhren BA, Homey B. Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors. Dermatology 2011;222(2):144-7
50. Allen KJ, Davis CL, Billings SD, Mousdicas N. Recalcitrant papulopustular rosacea in an immunocompetent patient responding to combination therapy with oral ivermectin and topical permethrin. Cutis 2007;80(2):149-51
51. Chhaiya SB, Patel VJ, Dave JN, et al. Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. Indian J Dermatol Venereol Leprol 2012;78(5):605-10
52. Bikowski JB, Del Rosso JQ. Demodex dermatitis: a retrospective analysis of clinical diagnosis and successful treatment with topical crotamiton. J Eur Acad Dermatol Venereol 2009;2(1):20-5
53. Stein L, Kircik L, Fowler J, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol 2014;13(3):316-23
54. Nielsen PG. A double-blind study of I% metronidazole cream versus systemic oxytetracycline therapy for rosacea. Br J Dermatol 1983;109(1):63-5
55. Miyachi Y. Potential antioxidant mechanism of action for metronidazole: implications for rosacea management. Adv Ther 2001;18(6): 237-43
56. Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Br J Dermatol 1998;134(6):679-83
57. Coda AB, Hata T, Miller J, et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol 2013;69(4):570-7
58. Czernielewski J, Liu Y. Comparison of 15% azelaic acid gel and 0.75% metronidazole gel for the topical treatment of papulopustular rosacea. Arch Dermatol 2004;140(10):1282-3
59. Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol 2003; 139(11):1444-50
60. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol 1999;40(6 Pt 1):961-5
61. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol 2003;48(6):836-45
62. Jorizzo JL, Lebwohl M, Tobey RE. The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial. J Am Acad Dermatol 1998;39(3):502-4
63. Gilchrest BA. Treatment of photodamage with topical tretinoin: an overview. J Am Acad Dermatol 1997;36(3 Pt 2):S27-36
64. Gilchrest BA, Holmes LB. Topical tretinoin: photodamage treatment overview and developmental toxicology studies. Introduction. J Am Acad Dermatol 1997; 36(3 Pt 2):S25-6
65. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol 1994;130(3):319-24
66. Kligman AM, Dogadkina D, Lavker RM. Effects of topical tretinoin on non-sun-exposed protected skin of the elderly. J Am Acad Dermatol 1993;29(1):25-33
67. Direct GM. Rosacea - pipeline review, H1 2013. 2013; (GMDHC3389IDB)
68. Hussein AA, Nicholls SJ. Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. Ther Clin Risk Manag 2010;6:183-90
69. Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol 1999; 127(1):20-6
70. Schwab VD, Sulk M, Seeliger S, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011;15(1):53-62
71. Cantor LB. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use. Expert Opin Pharmacother 2000;1(4):815-34
72. Galderma Laboratories LP. MIRVASO (brimonidine tartrate) gel [Galderma Laboratories, L.P.] DailyMed. Available from: http://dailymed.nlm.nih.gov/ dailymed/lookup.cfm?setid=f6a4353f-ae69-4214-901f-e5d42a6fbde7-nlm34090-1 [Last accessed 18 April 2014]
73. Agency EM. Assessment report: Mirvaso. 2013. Available from: www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/ human/002642/WC500163196.pdf [Last accessed 25 April 2014]
74. Burke J, Schwartz M. Preclinical evaluation of brimonidine. Survey Ophthalmol 1996; 41(Suppl 1):S9-18
75. Acheampong AA, Chien DS, Lam S, et al. Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase. Xenobiotica 1996;26(10):1035-55
76. Benkali K, Leoni M, Rony F, et al. Comparative pharmacokinetics and bioavailability of brimonidine following ocular administration and dermal application of brimonidine tartrate ophthalmic solution and gel in subjects with moderate to severe facial erythema of rosacea. Br J Dermatol 2014. [Epub ahead of print]
77. Fowler J, Jarratt M, Moore A, et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol 2012;166(3):633-41
78. Moore A, Kempers S, Murakawa G, et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol 2014;13(1):56-61
79. Routt ET, Levitt JO. Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%. J Am Acad Dermatol 2014;70(2):e37-8
80. Ilkovitch D, Pomerantz RG. Brimonidine effective but may lead to significant rebound erythema. J Am Acad Dermatol 2014;70(5): e109-10
81. Kim JH, Oh YS, Ji JH, et al. Rosacea (erythematotelangiectatic type) effectively improved by topical xylometazoline. J Dermatol 2011;38(5):510-13
82. Beck-Speier I, Dayal N, Karg E, et al. Oxymetazoline inhibits proinflammatory reactions: effect on arachidonic acid-derived metabolites. J Pharmacol Exp Ther 2006; 316(2):843-51
83. Del Rosso JQ. Management of facial erythema of rosacea: what is the role of topical alpha-adrenergic receptor agonist therapy? J Am Acad Dermatol 2013; 69(6 Suppl 1):S44-56
84. Galderma Laboratories LP. Mirvaso® (brimonidine) the first and only treatment targeting the facial redness of rosacea approved by the european commission. 2014. Available from: www.multivu.com/mnr/65011-mirvaso-first-and- only-treatmentrosacea [Last accessed 25 April 2014]
85. Bohm D, Schwanitz P, Stock Gissendanner S, et al. Symptom severity and psychological sequelae in rosacea: results of a survey. Psychol Health Med 2013. [Epub ahead of print]
86. Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol 1997;115(7):847-52
87. Adkins JC, Balfour JA. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging 1998;12(3):225-41